Inspire Investing LLC raised its stake in Haemonetics Corporation (NYSE:HAE – Free Report) by 5.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,441 shares of the medical instruments supplier’s stock after purchasing an additional 304 shares during the quarter. Inspire Investing LLC’s holdings in Haemonetics were worth $346,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of HAE. Quarry LP grew its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Haemonetics in the 1st quarter valued at approximately $65,000. Strs Ohio acquired a new stake in shares of Haemonetics in the 1st quarter valued at approximately $140,000. KBC Group NV lifted its holdings in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after buying an additional 401 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of Haemonetics by 71.5% in the 1st quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier’s stock valued at $200,000 after buying an additional 1,309 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
Get Haemonetics alerts:
Haemonetics Stock Down 2.3%
Shares of Haemonetics stock opened at $52.23 on Monday. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. The business’s 50 day simple moving average is $63.77 and its 200-day simple moving average is $65.38. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 15.97, a PEG ratio of 0.96 and a beta of 0.39. Haemonetics Corporation has a twelve month low of $50.68 and a twelve month high of $94.99.
Haemonetics (NYSE:HAE – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business had revenue of $321.39 million for the quarter, compared to analysts’ expectations of $305.12 million. During the same period in the prior year, the firm earned $1.02 EPS. The business’s quarterly revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have commented on HAE. Needham & Company LLC reiterated a “buy” rating and set a $68.00 target price (down from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Raymond James Financial downgraded Haemonetics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $105.00 to $78.00 in a research report on Monday, August 11th. Barrington Research lowered their price target on Haemonetics from $95.00 to $86.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus price target of $78.78.
Read Our Latest Report on HAE
About Haemonetics
(Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Five stocks we like better than Haemonetics
Low PE Growth Stocks: Unlocking Investment Opportunities
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
3 Fintech Stocks With Good 2021 Prospects
Football Season Is Here and DraftKings Stock Is Surging
3 Grocery Stocks That Are Proving They Are Still Essential
RH Stock Slides After Mixed Earnings and Tariff Concerns
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).
